Zobrazeno 51 - 57
of 57
pro vyhledávání: '"Elizabeth Ahern"'
Autor:
Elizabeth Ahern, Stacey Allen, Jing Liu, Juming Yan, Amy Roman Aguilera, Viviana P. Lutzky, Heidi Harjunpää, Michele W.L. Teng, Kazuyoshi Takeda, Stephen J. Blake, Camille Guillerey, Xian Yang Li, William C. Dougall, Deepak Mittal, Mark J. Smyth
Publikováno v:
OncoImmunology, Vol 7, Iss 7 (2018)
Multiple non-redundant immunosuppressive pathways co-exist in the tumor microenvironment and their co-targeting can increase clinical responses. Indeed, concurrent blockade of CTLA-4 and PD-1 in patients with advanced melanoma increased clinical resp
Autor:
Mark J. Smyth, Jake S. O’Donnell, Heidi Harjunpää, Michele W.L. Teng, William C. Dougall, Stacey Allen, Elizabeth Ahern
Publikováno v:
OncoImmunology, Vol 7, Iss 6 (2018)
Receptor activator of NF-κB ligand (RANKL) and its receptor RANK, are members of the tumor necrosis factor and receptor superfamilies, respectively. Antibodies targeting RANKL have recently been evaluated in combination with anti-CTLA4 in case repor
Autor:
Deborah S. Barkauskas, Kazuyoshi Takeda, Hideo Yagita, Elizabeth Ahern, David Wyld, Heidi Harjunpää, Michele W.L. Teng, Stacey Allen, Mark J. Smyth, William C. Dougall
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(19)
Purpose: Novel partners for established immune checkpoint inhibitors in the treatment of cancer are needed to address the problems of primary and acquired resistance. The efficacy of combination RANKL and CTLA4 blockade in antitumor immunity has been
Autor:
Mark J. Smyth, Deborah S. Barkauskas, Julia Reinhardt, Nicholas D. Huntington, Jennifer Landsberg, Tobias Bald, Arabella Young, Georgina V. Long, Shin Foong Ngiow, Glen M. Boyle, Michael Hölzel, Jai Rautela, Richard A. Scolyer, Elizabeth Ahern, Dirk Schadendorf, Jason Madore, Arash Chitsazan
Increasing evidence exists for the role of immunosuppressive adenosine in promoting tumor growth and spread in a number of cancer types, resulting in poor clinical outcomes. In this study, we assessed whether the CD73-adenosinergic pathway is active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fca14b2357dff513de5fa1b597eb91ee
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85027146573
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85027146573
Autor:
Mark J. Smyth, Michele W.L. Teng, Emma Ballard, Elizabeth Ahern, William C. Dougall, Brett G.M. Hughes, Annette Cubitt
Publikováno v:
Journal of Clinical Oncology. 37:TPS129-TPS129
TPS129 Background: Preclinical studies indicate Receptor Activator of NF-κB Ligand (RANKL) blockade improves anti-tumor efficacy of immune checkpoint blockade (ICB). Clinical trials combining denosumab (anti-RANKL mAb) with ICB are underway in vario
Autor:
Brett Gm, Hughes, Elizabeth, Ahern, Margot, Lehman, Gary, Pratt, Margaret, Dauth, Wendy, Pritchard, Leesa, Wockner, Keith, Horwood
Publikováno v:
Asia-Pacific journal of clinical oncology. 13(3)
Despite recent advances, outcomes for patients with stage III non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy (CRT) remain poor. We evaluated the combination of ciplatin/vinorelbine and concurrent thoracic radiotherapy followed b
Autor:
Rohini K. Hernandez, William C. Dougall, Mark J. Smyth, Sally W. Wade, Ronghai Bo, Elizabeth Ahern, Alexander Liede
Publikováno v:
Journal of Clinical Oncology. 36:e21001-e21001
e21001Background: After a case report of a melanoma (MEL) patient (pt) who had profound clinical response after treatment with an immune checkpoint inhibitor (ICI) and RANK-ligand inhibitor denosum...